CN111888372A - Formula and method for producing erythromycin ointment - Google Patents

Formula and method for producing erythromycin ointment Download PDF

Info

Publication number
CN111888372A
CN111888372A CN202010835784.5A CN202010835784A CN111888372A CN 111888372 A CN111888372 A CN 111888372A CN 202010835784 A CN202010835784 A CN 202010835784A CN 111888372 A CN111888372 A CN 111888372A
Authority
CN
China
Prior art keywords
parts
erythromycin
medicinal powder
base material
zinc oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010835784.5A
Other languages
Chinese (zh)
Inventor
盛暑溧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Eyecare Pharmaceutical Co ltd
Original Assignee
Anhui Eyecare Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Eyecare Pharmaceutical Co ltd filed Critical Anhui Eyecare Pharmaceutical Co ltd
Priority to CN202010835784.5A priority Critical patent/CN111888372A/en
Publication of CN111888372A publication Critical patent/CN111888372A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8994—Coix (Job's tears)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a production formula of erythromycin ointment, which comprises the following raw materials in parts by weight: 30-46 parts of erythromycin compounds, 12-14 parts of zinc oxide, 8-13 parts of medicinal powder extract, 20-25 parts of base material, 5-9 parts of metronidazole and the balance of water; the medicinal powder of the medicinal powder extract is the same mass of mugwort, angelica dahurica, calamus, rhizoma atractylodis, phellodendron, coix seed, coptis chinensis and liquorice; the base material is a mixture of glyceryl monostearate, octadecanol, 1, 3-propylene glycol, glyceryl citrate stearate and water with the same mass. The erythromycin ointment has the effects of resisting bacteria, sterilizing, diminishing inflammation, promoting blood circulation, removing blood stasis and relieving swelling by adding the medicinal powder extract and the erythromycin compounds, and the effects of medicine release and transdermal absorption are improved; the zinc oxide has astringent and protective effects, and can prevent skin damage caused by erythromycin ointment; the addition of the base material has the effects of retaining water for skin, preventing the loss of effective components of the medicine and prolonging the action time of the medicine.

Description

Formula and method for producing erythromycin ointment
Technical Field
The invention relates to the technical field of erythromycin ointment, and particularly relates to a production formula and a production method of erythromycin ointment.
Background
Erythromycin ointment is an antibacterial drug, mainly has antibacterial effect, and belongs to macrolide antibacterial drugs. The existing erythromycin ointment has few formula components, particularly, erythromycin compounds are mostly single erythromycin, the effects of drug release and transdermal absorption are poor, so that the efficacy is poor, meanwhile, the loss of effective components is serious, and the action time of the drugs is poor.
Disclosure of Invention
The invention aims to solve the defects in the prior art and provides a production formula and a production method of erythromycin ointment.
In order to achieve the purpose, the invention adopts the following technical scheme:
the formula for producing the erythromycin ointment comprises the following raw materials in parts by weight: 30-46 parts of erythromycin compounds, 12-14 parts of zinc oxide, 8-13 parts of medicinal powder extract, 20-25 parts of base material, 5-9 parts of metronidazole and the balance of water; the medicinal powder of the medicinal powder extract is the same mass of mugwort, angelica dahurica, calamus, rhizoma atractylodis, phellodendron, coix seed, coptis chinensis and liquorice; the base material is a mixture of glyceryl monostearate, octadecanol, 1, 3-propylene glycol, glyceryl citrate stearate and water with the same mass.
Preferably, the raw materials are as follows by weight: 30 parts of erythromycin compounds, 12 parts of zinc oxide, 8 parts of medicinal powder extract, 20 parts of base material, 5 parts of metronidazole and the balance of water.
Preferably, the raw materials are as follows by weight: 38 parts of erythromycin compounds, 13 parts of zinc oxide, 10 parts of medicinal powder extract, 22 parts of base material, 8 parts of metronidazole and the balance of water.
Preferably, the raw materials are as follows by weight: 46 parts of erythromycin compounds, 14 parts of zinc oxide, 13 parts of medicinal powder extract, 25 parts of base material, 9 parts of metronidazole and the balance of water.
Preferably, the auxiliary material is a mixture of yellow vaseline and soft liquid paraffin, wherein the ratio of yellow vaseline to soft liquid paraffin is 4: 6.
Preferably, the erythromycin compound is a mixture of erythromycin, erythromycin thiocyanate and erythromycin ethylsuccinate, wherein the ratio of erythromycin, erythromycin thiocyanate and erythromycin ethylsuccinate is 4: 3.
A method for producing erythromycin ointment comprises the following steps:
s1: concentrating the medicinal powder extract under pressure of 300-750mmHg to obtain paste extract, adding zinc oxide, erythromycin compounds, and metronidazole into the paste extract, and stirring to obtain paste mixture;
s2, adding the pasty mixture into the base material, stirring to completely dissolve the medicine, shearing and emulsifying for 30-60 minutes, filtering, and naturally cooling the filtrate to room temperature to obtain sulfur ointment;
s3: the sulfur ointment is packaged in a medicament bottle in a sealing way, the sterilization treatment of the mouth of the medicament bottle needs to be paid attention to during subpackage, and the medicament bottle is a light-tight medicament bottle.
Compared with the prior art, the invention has the beneficial effects that: the erythromycin ointment has the effects of resisting bacteria, sterilizing, diminishing inflammation, promoting blood circulation, removing blood stasis and diminishing swelling, and improves the effects of drug release and transdermal absorption; the zinc oxide has astringent and protective effects, and can prevent skin damage caused by erythromycin ointment; the addition of the base material has the effects of retaining water for skin, preventing the loss of effective components of the medicine and prolonging the action time of the medicine.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Example 1
The formula for producing the erythromycin ointment comprises the following raw materials in parts by weight: 30 parts of erythromycin compounds, 12 parts of zinc oxide, 8 parts of medicinal powder extract, 20 parts of base material, 5 parts of metronidazole and the balance of water; the medicinal powder of the medicinal powder extract is the same mass of mugwort, angelica dahurica, calamus, rhizoma atractylodis, phellodendron, coix seed, coptis chinensis and liquorice; the base material is a mixture of glyceryl monostearate, octadecanol, 1, 3-propylene glycol, glyceryl citrate stearate and water with the same mass.
Specifically, the auxiliary material is a mixture of yellow vaseline and soft liquid paraffin, wherein the ratio of the yellow vaseline to the soft liquid paraffin is 4: 6.
Specifically, the erythromycin compound is a mixture of erythromycin, erythromycin thiocyanate and erythromycin ethylsuccinate, wherein the ratio of erythromycin, erythromycin thiocyanate and erythromycin ethylsuccinate is 4: 3.
A method for producing erythromycin ointment comprises the following steps:
s1: concentrating the medicinal powder extract under 300mmHg to obtain paste extract, adding zinc oxide, erythromycin compounds, and metronidazole into the paste extract, and stirring to obtain paste mixture;
s2, adding the pasty mixture into the base material, stirring to completely dissolve the medicine, shearing and emulsifying for 30 minutes, filtering, and naturally cooling the filtrate to room temperature to obtain sulfur ointment;
s3: the sulfur ointment is packaged in a medicament bottle in a sealing way, the sterilization treatment of the mouth of the medicament bottle needs to be paid attention to during subpackage, and the medicament bottle is a light-tight medicament bottle.
Example 2
The formula for producing the erythromycin ointment comprises the following raw materials in parts by weight: 38 parts of erythromycin compounds, 13 parts of zinc oxide, 10 parts of medicinal powder extract, 22 parts of base material, 8 parts of metronidazole and the balance of water; the medicinal powder of the medicinal powder extract is the same mass of mugwort, angelica dahurica, calamus, rhizoma atractylodis, phellodendron, coix seed, coptis chinensis and liquorice; the base material is a mixture of glyceryl monostearate, octadecanol, 1, 3-propylene glycol, glyceryl citrate stearate and water with the same mass.
Specifically, the auxiliary material is a mixture of yellow vaseline and soft liquid paraffin, wherein the ratio of the yellow vaseline to the soft liquid paraffin is 4: 6.
Specifically, the erythromycin compound is a mixture of erythromycin, erythromycin thiocyanate and erythromycin ethylsuccinate, wherein the ratio of erythromycin, erythromycin thiocyanate and erythromycin ethylsuccinate is 4: 3.
A method for producing erythromycin ointment comprises the following steps:
s1: concentrating the medicinal powder extract under 550mmHg to obtain paste extract, adding zinc oxide, erythromycin compounds, and metronidazole into the paste extract, and stirring to obtain paste mixture;
s2, adding the pasty mixture into the base material, stirring to completely dissolve the medicine, shearing and emulsifying for 50 minutes, filtering, and naturally cooling the filtrate to room temperature to obtain sulfur ointment;
s3: the sulfur ointment is packaged in a medicament bottle in a sealing way, the sterilization treatment of the mouth of the medicament bottle needs to be paid attention to during subpackage, and the medicament bottle is a light-tight medicament bottle.
Example 3
The formula for producing the erythromycin ointment comprises the following raw materials in parts by weight: 46 parts of erythromycin compounds, 14 parts of zinc oxide, 13 parts of medicinal powder extract, 25 parts of base material, 9 parts of metronidazole and the balance of water; the medicinal powder of the medicinal powder extract is the same mass of mugwort, angelica dahurica, calamus, rhizoma atractylodis, phellodendron, coix seed, coptis chinensis and liquorice; the base material is a mixture of glyceryl monostearate, octadecanol, 1, 3-propylene glycol, glyceryl citrate stearate and water with the same mass.
Specifically, the auxiliary material is a mixture of yellow vaseline and soft liquid paraffin, wherein the ratio of the yellow vaseline to the soft liquid paraffin is 4: 6.
Specifically, the erythromycin compound is a mixture of erythromycin, erythromycin thiocyanate and erythromycin ethylsuccinate, wherein the ratio of erythromycin, erythromycin thiocyanate and erythromycin ethylsuccinate is 4: 3.
A method for producing erythromycin ointment comprises the following steps:
s1: concentrating the medicinal powder extract under 750mmHg to obtain paste extract, adding zinc oxide, erythromycin compounds, and metronidazole into the paste extract, and stirring to obtain paste mixture;
s2, adding the pasty mixture into the base material, stirring to completely dissolve the medicine, shearing and emulsifying for 60 minutes, filtering, and naturally cooling the filtrate to room temperature to obtain sulfur ointment;
s3: the sulfur ointment is packaged in a medicament bottle in a sealing way, the sterilization treatment of the mouth of the medicament bottle needs to be paid attention to during subpackage, and the medicament bottle is a light-tight medicament bottle.
The erythromycin ointment has the effects of resisting bacteria, sterilizing, diminishing inflammation, promoting blood circulation, removing blood stasis and diminishing swelling, and improves the effects of drug release and transdermal absorption; the zinc oxide has astringent and protective effects, and can prevent skin damage caused by erythromycin ointment; the addition of the base material has the effects of retaining water for skin, preventing the loss of effective components of the medicine and prolonging the action time of the medicine.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.

Claims (7)

1. The production formula of the erythromycin ointment is characterized in that: the raw materials are as follows by weight: 30-46 parts of erythromycin compounds, 12-14 parts of zinc oxide, 8-13 parts of medicinal powder extract, 20-25 parts of base material, 5-9 parts of metronidazole and the balance of water; the medicinal powder of the medicinal powder extract is the same mass of mugwort, angelica dahurica, calamus, rhizoma atractylodis, phellodendron, coix seed, coptis chinensis and liquorice; the base material is a mixture of glyceryl monostearate, octadecanol, 1, 3-propylene glycol, glyceryl citrate stearate and water with the same mass.
2. The formulation of claim 1, wherein the formulation comprises: the raw materials are as follows by weight: 30 parts of erythromycin compounds, 12 parts of zinc oxide, 8 parts of medicinal powder extract, 20 parts of base material, 5 parts of metronidazole and the balance of water.
3. The formulation of claim 1, wherein the formulation comprises: the raw materials are as follows by weight: 38 parts of erythromycin compounds, 13 parts of zinc oxide, 10 parts of medicinal powder extract, 22 parts of base material, 8 parts of metronidazole and the balance of water.
4. The formulation of claim 1, wherein the formulation comprises: the raw materials are as follows by weight: 46 parts of erythromycin compounds, 14 parts of zinc oxide, 13 parts of medicinal powder extract, 25 parts of base material, 9 parts of metronidazole and the balance of water.
5. The formulation of claim 1, wherein the formulation comprises: the auxiliary material is a mixture of yellow vaseline and soft liquid paraffin, wherein the ratio of the yellow vaseline to the soft liquid paraffin is 4: 6.
6. The formulation of claim 1, wherein the formulation comprises: the erythromycin compounds are a mixture of erythromycin, erythromycin thionate and erythromycin ethylsuccinate, wherein the ratio of erythromycin, erythromycin thionate and erythromycin ethylsuccinate is 4: 3.
7. A method of producing an erythromycin ointment as claimed in claim 1, characterized in that:
the method comprises the following steps:
s1: concentrating the medicinal powder extract under pressure of 300-750mmHg to obtain paste extract, adding zinc oxide, erythromycin compounds, and metronidazole into the paste extract, and stirring to obtain paste mixture;
s2, adding the pasty mixture into the base material, stirring to completely dissolve the medicine, shearing and emulsifying for 30-60 minutes, filtering, and naturally cooling the filtrate to room temperature to obtain sulfur ointment;
s3: the sulfur ointment is packaged in a medicament bottle in a sealing way, the sterilization treatment of the mouth of the medicament bottle needs to be paid attention to during subpackage, and the medicament bottle is a light-tight medicament bottle.
CN202010835784.5A 2020-08-19 2020-08-19 Formula and method for producing erythromycin ointment Pending CN111888372A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010835784.5A CN111888372A (en) 2020-08-19 2020-08-19 Formula and method for producing erythromycin ointment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010835784.5A CN111888372A (en) 2020-08-19 2020-08-19 Formula and method for producing erythromycin ointment

Publications (1)

Publication Number Publication Date
CN111888372A true CN111888372A (en) 2020-11-06

Family

ID=73230013

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010835784.5A Pending CN111888372A (en) 2020-08-19 2020-08-19 Formula and method for producing erythromycin ointment

Country Status (1)

Country Link
CN (1) CN111888372A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114632139A (en) * 2022-04-02 2022-06-17 北京双吉制药有限公司 Erythromycin ointment and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101732335A (en) * 2009-12-08 2010-06-16 辽宁中医药大学 Ointment medicament for treating acne and production method thereof
CN102716380A (en) * 2012-07-04 2012-10-10 甘肃省商业科技研究所 Compound acne-removal cream and production method thereof
CN106727283A (en) * 2016-12-26 2017-05-31 侯俊领 It is a kind of to treat metronidazole erythromycin compound ointment of face acnes and preparation method thereof
CN110934956A (en) * 2020-01-01 2020-03-31 吕银山 Acne removing cream

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101732335A (en) * 2009-12-08 2010-06-16 辽宁中医药大学 Ointment medicament for treating acne and production method thereof
CN102716380A (en) * 2012-07-04 2012-10-10 甘肃省商业科技研究所 Compound acne-removal cream and production method thereof
CN106727283A (en) * 2016-12-26 2017-05-31 侯俊领 It is a kind of to treat metronidazole erythromycin compound ointment of face acnes and preparation method thereof
CN110934956A (en) * 2020-01-01 2020-03-31 吕银山 Acne removing cream

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114632139A (en) * 2022-04-02 2022-06-17 北京双吉制药有限公司 Erythromycin ointment and preparation method thereof
CN114632139B (en) * 2022-04-02 2023-04-07 北京双吉制药有限公司 Erythromycin ointment and preparation method thereof

Similar Documents

Publication Publication Date Title
CN103110868A (en) Skin care solution and preparation method thereof
EA029649B1 (en) Pomegranate-peel polyphenol gel used to treat gynecological inflammation diseases and method for preparation thereof
CN102008612B (en) Medicament for treating empyrosis and preparation method thereof
CN111888372A (en) Formula and method for producing erythromycin ointment
CN102429986A (en) Traditional Chinese ointment for treating burn and scald and preparation method thereof
CN111297961A (en) Dong medicine for promoting wound healing
CN109010525B (en) Herbal enzyme ointment for treating eczema and preparation method and application thereof
CN104815068A (en) Cefalexin ointment and preparation method thereof
CN115068386A (en) Toothpaste containing calendula officinalis mixed extract and preparation method thereof
CN112426563A (en) Liquid dressing prepared from myrtle extract and compounding method thereof
CN113813308A (en) Medicine for treating burn and scald and preparation method thereof
CN103191232B (en) Traditional Chinese medicine composition for preventing and treating mastitis of dairy cattle and preparation and application of composition
CN108578418B (en) Combined medicine for treating diabetic wound complications
CN102920800B (en) Topical drug composite and application and preparation method thereof
CN101766731B (en) Tea polyphenol acne resistant external preparation
CN105536028A (en) Dressing for promoting skin wound repair and preparing method
CN111150789A (en) Medicinal liquor for treating traumatic injury and preparation method thereof
CN111686189B (en) Plant composition for treating red wind buttocks and application thereof
CN116440222B (en) Traditional Chinese medicine composition for resisting bacteria and whitening skin
CN103263523B (en) A kind of for breast perfusion preparation preventing and treating mastitis and preparation method thereof
CN111437343B (en) Inflammation-diminishing and pain-relieving composition, carthamus tinctorius inflammation-diminishing and pain-relieving liquid and preparation method thereof
EP4104875B1 (en) Corrosion-resistant stoma leakage-proof paste capable of achieving self-regulation of strength and preparation method therefor
CN111840479A (en) Formula and production process of sulfur ointment
CN109432290B (en) Traditional Chinese medicine composition with skin anti-allergy effect and aqueous extract and fermentation product and application thereof
CN109745263B (en) Compound traditional Chinese medicine toothpaste containing subprostrate sophora and pseudo-ginseng and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20201106

RJ01 Rejection of invention patent application after publication